Treat-And-Extend Versus Pro Re Nata Regimen of Intravitreal Conbercept Injection for Neovascular Age-Related Macular Degeneration: Results from COCOA, a Prospective, Open-Label, Multicenter, Randomized Phase IV Clinical Trial

Purpose To evaluate and contrast the effectiveness and safety of two conbercept treatment protocols—a three-dose treat-and-extend (3+T&E) regimen and a three-dose pro re nata (3+PRN) regimen—in Chinese patients diagnosed with neovascular age-related macular degeneration (nAMD).